Literature DB >> 17072636

Prognosis of untreated occult choroidal neovascularization.

Ilse Krebs1, Ulrike Stolba, Carl Glittenberg, Orang Seyeddain, Thomas Benesch, Susanne Binder.   

Abstract

PURPOSE: The aim of this investigation was to evaluate prognostic factors influencing the short-term prognosis of occult choroidal neovascularization (CNV).
METHODS: A consecutive series of 107 untreated occult CNV in 101 patients were evaluated in terms of the effect of their initial lesion characteristics, as determined with fluorescein angiography (FA), indocyanine green angiography (ICG-A) and optical coherence tomography (OCT), on the change in distance acuity, lesion size and retinal thickness over 1-3 months. Descriptive statistics, the Pearson Correlation Coefficient and a multiple linear regression analysis were applied to treat the data.
RESULTS: A total of 107 eyes (101 patients) were examined. The study cohort consisted of 35 males and 66 females, with a mean age of 77.6 years. During the 3-month study period the mean distance acuity decreased from 67.0 to 63.2 letters; the mean size of the lesion increased from 16.1 to 18.4 mm(2); the mean maximum retinal thickness increased from 374.5 to 387.5 mum. Of the lesions, 59.8% included pigment epithelial detachments (serous or fibrovascular) and 29.9% retinal angiomatous proliferation. A better distance acuity at both visits for the entire study population correlated significantly with smaller lesions, as determined by FA and ICG-A (p < 0.0001), and a lower maximum retinal thickness, as determined by the OCT (p < 0.0001).
CONCLUSIONS: A small and statistically insignificant change in distance acuity, lesion size and retinal thickness occurred over the 3 months of the study period. This reduced the ability of the study to examine the effect of baseline findings on outcome. Only two factors - the presence of a RAP lesion or the presence of CNV in the other eye - significantly and adversely affected the distance visual acuity at follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072636     DOI: 10.1007/s00417-006-0424-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  26 in total

1.  Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy.

Authors:  Ilse Krebs; Susanne Binder; Ulrike Stolba; Carl Glittenberg; Werner Brannath; Alexandra Goll
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

2.  Optical coherence tomography guided retreatment of photodynamic therapy.

Authors:  I Krebs; S Binder; U Stolba; K Schmid; C Glittenberg; W Brannath; A Goll
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-09

4.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.

Authors:  Neil M Bressler
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

5.  Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1997-06

6.  Unfavorable effect of photodynamic therapy for late subretinal neovascularization with chorioretinal anastomoses associated with idiopathic multiple serous detachments of the retinal pigment epithelium.

Authors:  M Fossarello; E Peiretti; I Zucca; A Serra
Journal:  Eur J Ophthalmol       Date:  2004 Nov-Dec       Impact factor: 2.597

7.  Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration.

Authors:  J S Slakter; L A Yannuzzi; U Schneider; J A Sorenson; A Ciardella; D R Guyer; R F Spaide; K B Freund; D A Orlock
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

8.  Occult choroidal neovascularization in age-related macular degeneration. A natural history study.

Authors:  T S Stevens; N M Bressler; M G Maguire; S B Bressler; S L Fine; J Alexander; D A Phillips; R R Margherio; P L Murphy; A P Schachat
Journal:  Arch Ophthalmol       Date:  1997-03

9.  Retinal angiomatous proliferation: clinical characteristics and treatment options.

Authors:  Megan A Hunter; Mark T Dunbar; Phillip J Rosenfeld
Journal:  Optometry       Date:  2004-09

10.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

Authors:  Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

View more
  3 in total

1.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

2.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

Review 3.  Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study.

Authors:  Mari Elshout; Carroll A Webers; Margriet I van der Reis; Yvonne de Jong-Hesse; Jan S Schouten
Journal:  BMC Ophthalmol       Date:  2017-07-11       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.